<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278004</url>
  </required_header>
  <id_info>
    <org_study_id>CCR3116</org_study_id>
    <nct_id>NCT01278004</nct_id>
  </id_info>
  <brief_title>Chemotherapy Induced Painful Peripheral Neuropathy Ethosuximide (The CIN-E Study)</brief_title>
  <acronym>CINE-E</acronym>
  <official_title>A Randomised Double-blind Placebo-controlled Trial of the Safety and Efficacy of Ethosuximide 250mg Capsules for the Management of Chemotherapy Induced Painful Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a drug trial of ethosuximide as a painkiller if you develop pain as a side
      effect of chemotherapy. Ethosuximide will be compared against placebo (an inactive substance)
      to test whether any response is a true effect of the drug, and not a 'placebo effect'.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in pain intensity from baseline to endpoint as assessed on a Numerical Pain Rating scale.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cancer</condition>
  <condition>Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethosuximide</intervention_name>
    <description>Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18

          -  Diagnosis of cancer

          -  Willing and able to give informed consent to the CIN-E study and complete study
             questionnaires, this involves adequate understanding of written and spoken English
             (translators will not be used)

          -  Chemotherapy-induced painful peripheral neuropathy as diagnosed by score of &gt;12 on the
             Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) with a pain intensity
             rating of &gt;4, on a 11 point numeric rating scale (0= no pain, 10= worst possible
             pain).

          -  Duration of chemotherapy-induced painful peripheral neuropathy &gt;4 weeks. Participant
             may either have completed chemotherapy, or be receiving ongoing chemotherapy.

          -  Able to attend research centre according to the required visit schedule.

          -  Diet allows bovine gelatine (present in both ethosuximide and placebo capsules)

          -  Women of child-bearing potential must be using a reliable form of contraception i.e.
             oral contraceptives, a barrier method (condom or diaphragm), intra-uterine device or
             abstinence.

        Exclusion Criteria:

          -  Renal impairment (serum creatinine &gt;1.5x normal level)

          -  Deranged liver function (AST&gt;3x normal level)

          -  Patients currently taking any anti-depressant medication, for example fluoxetine,
             paroxetine, citalopram, venlafaxine, amitriptyline, or within the past week.

          -  Patients currently taking any other anti-epileptic drug, including gabapentin, or
             within the past week.

          -  Pregnancy

          -  Allergy to succinimides, ethosuximide, methsuximide, phensuximide. Pre-exisitng
             painful peripheral neuropathy of any other cause.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult cancer patients with chemotherapy-induced painful peripheral neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethosuximide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

